{"title":"杨森生物技术授权安斯泰来口服JAK抑制剂ASP015K在日本以外的权利","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I10.1821","DOIUrl":null,"url":null,"abstract":"In a bid to strengthen its autoimmune disease franchise, Johnson & Johnson’s Janssen Biotech has licensed worldwide rights, excluding Japan, to develop and commercialise Astellas Pharma’s ASP015K, a Janus kinase (JAK) inhibitor in Phase IIb development for moderate-to-severe rheumatoid arthritis (RA). J&J already markets the anti-TNF-alpha (anti-tumour necrosis factor alpha) agents Remicade® (infliximab) and Simponi® (golimumab). Pfizer’s tofacitinib is poised to be the first JAK inhibitor to be approved for the treatment of RA with a regulatory decision expected from the US FDA in November 2012.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Janssen Biotech Licenses Ex-Japan Rights to Astellas’ Oral JAK Inhibitor ASP015K\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I10.1821\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In a bid to strengthen its autoimmune disease franchise, Johnson & Johnson’s Janssen Biotech has licensed worldwide rights, excluding Japan, to develop and commercialise Astellas Pharma’s ASP015K, a Janus kinase (JAK) inhibitor in Phase IIb development for moderate-to-severe rheumatoid arthritis (RA). J&J already markets the anti-TNF-alpha (anti-tumour necrosis factor alpha) agents Remicade® (infliximab) and Simponi® (golimumab). Pfizer’s tofacitinib is poised to be the first JAK inhibitor to be approved for the treatment of RA with a regulatory decision expected from the US FDA in November 2012.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-10-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I10.1821\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I10.1821","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Janssen Biotech Licenses Ex-Japan Rights to Astellas’ Oral JAK Inhibitor ASP015K
In a bid to strengthen its autoimmune disease franchise, Johnson & Johnson’s Janssen Biotech has licensed worldwide rights, excluding Japan, to develop and commercialise Astellas Pharma’s ASP015K, a Janus kinase (JAK) inhibitor in Phase IIb development for moderate-to-severe rheumatoid arthritis (RA). J&J already markets the anti-TNF-alpha (anti-tumour necrosis factor alpha) agents Remicade® (infliximab) and Simponi® (golimumab). Pfizer’s tofacitinib is poised to be the first JAK inhibitor to be approved for the treatment of RA with a regulatory decision expected from the US FDA in November 2012.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
